First Time Loading...
Y

Yabao Pharmaceutical Group Co Ltd
SSE:600351

Watchlist Manager
Yabao Pharmaceutical Group Co Ltd
SSE:600351
Watchlist
Price: 6.68 CNY -0.3% Market Closed
Updated: May 13, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
Yabao Pharmaceutical Group Co Ltd

Wall Street analysts forecast Yabao Pharmaceutical Group Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Yabao Pharmaceutical Group Co Ltd is 10.8 CNY .

Lowest Forecast
Wall Street Target
Not Available
Average Forecast
Wall Street Target
10.8 CNY
62% Upside
Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
10.8 CNY
62% Upside
Highest
Price Target
Not Available
Yabao Pharmaceutical Group Co Ltd Competitors:
Price Targets
PFE
Pfizer Inc
13% Upside
O
ORNBV
Orion Oyj
5% Upside
BMY
Bristol-Myers Squibb Co
18% Upside
P
300363
Porton Pharma Solutions Ltd
60% Upside
PFE
Pfizer Inc
13% Upside
O
ORNBV
Orion Oyj
5% Upside
BMY
Bristol-Myers Squibb Co
18% Upside
P
300363
Porton Pharma Solutions Ltd
60% Upside
R
RHONEMA
Rhone Ma Holdings Bhd
16% Upside
PHAT
Phathom Pharmaceuticals Inc
145% Upside
SCTL
Societal CDMO Inc
0% Downside
000952
Hubei Guangji Pharmaceutical Co Ltd
518% Upside

Revenue
Forecast

Revenue Estimate
Yabao Pharmaceutical Group Co Ltd

For the last 8 years the compound annual growth rate for Yabao Pharmaceutical Group Co Ltd's revenue is 5%. The projected CAGR for the next 4 years is 4%.

5%
Past Growth
4%
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Yabao Pharmaceutical Group Co Ltd

For the last 8 years the compound annual growth rate for Yabao Pharmaceutical Group Co Ltd's operating income is -2%. The projected CAGR for the next 8 years is 1%.

-2%
Past Growth
1%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Yabao Pharmaceutical Group Co Ltd

For the last 8 years the compound annual growth rate for Yabao Pharmaceutical Group Co Ltd's net income is -6%. The projected CAGR for the next 4 years is 25%.

-6%
Past Growth
25%
Estimated Growth
Estimates Accuracy
-8%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Yabao Pharmaceutical Group Co Ltd's stock price target?
Price Target
10.8 CNY

According to Wall Street analysts, the average 1-year price target for Yabao Pharmaceutical Group Co Ltd is 10.8 CNY .

What is Yabao Pharmaceutical Group Co Ltd's Revenue forecast?
Projected CAGR
4%

For the last 8 years the compound annual growth rate for Yabao Pharmaceutical Group Co Ltd's revenue is 5%. The projected CAGR for the next 4 years is 4%.

What is Yabao Pharmaceutical Group Co Ltd's Operating Income forecast?
Projected CAGR
1%

For the last 8 years the compound annual growth rate for Yabao Pharmaceutical Group Co Ltd's operating income is -2%. The projected CAGR for the next 8 years is 1%.

What is Yabao Pharmaceutical Group Co Ltd's Net Income forecast?
Projected CAGR
25%

For the last 8 years the compound annual growth rate for Yabao Pharmaceutical Group Co Ltd's net income is -6%. The projected CAGR for the next 4 years is 25%.

ALPHA SPREAD
Join more than 136,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.